

SimVis Gekko

Let patients experience
their future vision—
before surgery.



2EyesVision

www.2eyesvision.com






Cataract and presbyopia are two of the leading ocular conditions with higher prevalence worldwide

Cataracts

Opacifications in the eye due to natural process of aging

>50% of the population over the age of 75

~30 million surgeries in 2024



Presbyopia

Hard to see **near objects** due to natural process of aging

>80% of the population over the age of 50

~2,1 billion people in 2024





Cataract & Presbyopia Surgery: A Growing Unmet Need

An increasing number of multifocal alternatives for patients makes choosing the right implant challenging



Is this a **suitable candidate** for a premium presbyopic correction?
Will this be a **happy patient**?

How am I going to see with the treatment?



SimVis Gekko2™



An innovative visual simulator that allows patients to see the **real world through various multifocal corrections prior to surgery/treatment:**

- ✓ Clinically-proven more than 30 published articles and 5 international patent families
- ✓ Key Opinion Leader (KOL)-endorsed
- ✓ Proven efficacy with foundational version in 18 countries world-wide



Ministry of Food and Drug Safety



2EyesVision




Our addressable market is expected to sustain strong growth, driven by favorable market tailwinds

Key Market Drivers


1 Demographics – ageing population

Population +60 years old



Population projections per group with higher risk to presbyopia and cataracts, 2024-2050 [m people]

2 Penetration of multifocal procedures is **still low worldwide** but need for **more profitable** multifocal procedures, due to reimbursement challenges




Intraocular lens market segmentation, 2025 [% procedures]



2EyesVision's competitive advantage is strongly protected by four solid strategic pillars

2EyesVision MOAT





Go-To-Market Model: multi-channel strategy to reach eye clinics



User testimonials



"A picture is worth a thousand words. A simulation is worth a hundred thousand words"



Dr. Arthur Cummings



"It allows surgical candidates to test different presbyopia solutions. The concept of multifocality is better perceived by patients and this visual simulator can be easily implemented in the clinic's preoperative workflow, involving the patient in the decision-making process"



Dr. Filomena Ribeiro



"It just gives you a much more organic feeling"



I have used SimVis Gekko and it just gives you a much more organic feeling for how car lights generate dysphotopsia"

Dr. Scott M- MacRae





2Eyes Vision proposes a hybrid business model



One-time revenue



Recurring revenue



**Equipment
sale**

**Upfront
Fee**



**Device as a
service
(DaaS)**

Monthly subscription for rental, updates, tech service and renewal every 24 months

**Clinical as a
Service
(CaaS)**

DaaS + on-site clinical support once weekly



Eye clinic



Our management team is composed of seasoned executives with extensive experience in the ophthalmology sector

Overview of 2EyesVision's Management Team



Carlos Dorronsoro, PhD
CEO and co-founder of 2EV

- CSIC staff scientist (on leave for technology transfer)
- PhD in visual optics (University of Valladolid)
- Co-inventor of 23 patent families and 60+ research papers
- Promoter of 3 other startups (Imatrics Image Technologies, Alfa Imaging, Plenoptika)



Máximo Gómez
Chief Strategy Officer

- BA (UCM) and PADE (IESE Business School)
- +25 years of experience in the MedTech & Pharmaceutical industry, with 10 years in the ophthalmology sector
- Prior experience as a General Manager at Johnson & Johnson Spain and Abbott and MSD



Nivine Woods
Strategic Operating Partner USA

- Pharmacy (Cairo) and MBA (Texas)
- 20+ years of experience in the ophthalmic industry
- Prior roles in Alcon, Abbott, Johnson & Johnson Vision, and Eyecare Partners



Enrique Gambra, PhD
CTO

- PhD in visual sciences (University of Valladolid)
- 15+ years of experience in product development and R&D, mainly in eye diagnostic instruments
- Prior experience at I-Optics BV (NL) and CSIC



Xavier Pérez, MBA
CFO

- MBA (IESE Business School)
- 10+ years of experience in finance & strategy in the healthcare sector
- Prior experience in McKinsey, Roland Berger (consulting) and Sagetis Biotech



Alejandro García
Sales & Marketing Strategist

- Optometrist (UCM) and MBA (UNIR)
- 10+ years of experience in medical device sales in the ophthalmology sector
- Prior experience includes Visión Grupo Óptico, Visionlab, Instituto Oftalmológico Fernandez-Vega and Dive Medical



Pilar Urizar, PhD
Innovation Manager

- PhD in BioPhotonics (VioBio Lab CSIC)
- 5+ years of experience in the optical engineering field
- Prior experience at ASE Optics Europe



Diana Martín, PhD
Manufacturing Manager

- PhD in Physical Optics (Universidad Complutense de Madrid)
- 15+ years of experience in manufacturing, quality control and regulatory in the ophthalmology sector
- Prior experience in CSIC and DermaLumics



We rely on a world-class medical advisory board with renowned key opinion leaders at a global scale

Medical Advisory Board



Dr. Daniel S. Durrie

Overland Park, KS, United States
Refractive surgery specialist



Susana Marcos, PhD

Rochester, NY, United States
Co-founder and member of advisory board



Dr. Jay Pepose

St Louis, MO, United States
LASIK surgery specialist



Dr. Kendall Donaldson

Miami, FL, United States
Cornea specialist at Bascom Palmer Eye Institute



Dr. Phil Hoopes

Draper, UT, United States
LASIK surgery specialist



Dr. Vance Thompson

Sioux Falls, SD, United States
Refractive & cataract surgery specialist



Dr. Scott Macrae

Rochester, NY, United States
Cornea specialist



Dr. Paul Karpecki

Louisville, KY, United States
Optometry leader & Dry Eye specialist



Dr. George Waring IV

Mount Pleasant, SC, United States
Refractive surgery specialist







Our growth plans include reaching >1.300 eye clinics in key countries¹⁾, 7% market share by 2030

2Eyes Vision Financial Projections – Summary

Annual units sold



Installed base, accumulated units



Hypothesis

Market share

- Number of clinics in key countries: 20.263
- Annual multifocal surgeries per clinic: 100
- Key countries: 77% of total market in 2025

1) United States, Japan, Germany, France, Italy, Spain, the United Kingdom, Canada, Australia, South Korea, China, India, and Brazil


Source: 2Eyes Vision




We plan to reach EUR 10 m in revenue by 2030, and positive EBITDA in 2028

2Eyes Vision Financial Estimates – Summary

Net revenues, by geography, m€



EBITDA margin, m€; %



Hypothesis

Average Selling Price

- 16.700€ in 2026

Sales by channel:

- **Direct sales:** Spain/ Portugal/ others
- **Indirect sales:** Rest of territories
 - **Channel Fee:** 35% (current share to distributors)
- **US.** LMR in 2-3 PE-backed groups prior to national distribution partnership
- **APAC.** China + S Korea (both in progress) followed by India launch




We are raising a Series A of 5M € to prepare the company for an exit – 5M € to be covered in 2026-2027 period

■ Pre-Series A ■ Series A




+ additional 500.000€ of Non-dilutive funding committed in 2026-28

We will use the funding to accelerate growth in key markets and prepare the company for an EXIT



Milestones





2EyesVision is a deep tech company already in the market of ophthalmology, with a convincing investment opportunity

Investment highlights



Notable unmet need with strong tailwinds thanks to demographics and reimbursement challenges

- **Cataracts:** opacifications in the eye due to natural process of aging – Affecting >50% of the population over the age of 75 and ~30 m surgeries in 2025
- **Presbyopia:** hard to see near objects due to natural process of aging – Affecting >80% of the population over the age of 50 or ~2,1 billion people in 2025



A unique, category-defining solution

- **Revolutionary visual simulation technology** for an accurate and personalized experience of premium multifocal corrections. Lead by a **Management team** composed of seasoned executives with extensive experience in the ophthalmology sector,
- **Strong body of evidence** (30+ articles) **and experience** (~20 countries), which is second to none.



Strong defensibility (MOAT)

- **Protected by IP, proprietary optical know-how, and the ability to build proprietary data with predictive power.**



Business potential in the global market

- **Scalability.** Hybrid model combining device deployment with subscription-based services
- **Proven clinical and economic value to clinics.** Improves patient satisfaction, shared decision-making, and conversion to premium procedures.
- **Global expansion roadmap,**



Potential exit strategy in a very active market

- **Different potential buyers' profiles** that might be interested in acquiring 2EyesVision (e.g., leading IOL manufacturers, leading ophthalmology device manufacturers, medical device companies, medical device distributors, etc.)
- **M&A activity** in the IOL and ophthalmology market is **high**, with leading players investing in new technology and products

2EyesVision shows **strong value creation potential** for expansion across the world





Let's explore the future of vision together!

Máximo Gómez
Chief Strategy Officer
mgomez@2eyesvision.com



SimVis Gekko positioned as a best-in-class of a new category

Overview of visual simulators of multifocal corrections

Player	HQ	Product name	Product type		Direct competitor	Product features					Intellectual Property	Scientific evidence
			Hardware	Software		Commercial IOLs	Binocular	Portable	See-through view	Programmable		
 2EyesVision		SimVis				✓	✓	✓	✓	✓		
 DEZIMAL MEDICAL ENGINEERING		RALV			✓	✓	X	X	✓	X		
 GreenMan		GreenMan			X	X	✓	✓	X	✓		
 Virtualens		Immersive IOL simulator			X	X	✓	✓	X	✓		
 VOPTICA SMART VISUAL OPT CS		VAO			X	X	X	X	X	✓		
 SBM Sistemi		Vision-AR-IOL			X	X	X	✓	X	X		
 KTH VETENSKAP OCH KONST		IOL-T2			X	✓	X	X	✓	X		

Source: Desk research, Expert interviews [reviewed in January 2026]